A

Abcam

Protein research tools that enable faster scientific breakthroughs

Cambridge, UK
1,800+

About Abcam

Industry: Life Sciences / Research Reagents
Founded: 1998
Founders: Jonathan Milner, Tony Kouzarides, David Cleevely
Status: Subsidiary of Danaher (acquired 2023; formerly Nasdaq: ABCM / AIM: ABC)

Funding & Growth

Total Raised: N/A (publicly traded until 2023 acquisition)
Valuation: Acquired by Danaher for ~$5.7B (Dec 2023)
Stage: Acquired — Danaher operating company
Key Investors:
Danaher Corporation

Pros

  • Backed by Danaher's scale and resources
  • Cutting-edge AI-driven protein design (LLMs, diffusion)
  • Cambridge Biomedical Campus location
  • Global leader in research antibodies & reagents
  • Autonomous-lab, fast design/make/test/learn cycles

Cons

  • Post-acquisition integration into a large corporation
  • Reagents focus is narrower than full therapeutics R&D
  • Some roles UK-based (relocation for US applicants)

🏢 Working Here

Abcam, founded in Cambridge, UK in 1998 and acquired by Danaher in December 2023, is a global supplier of protein research tools — research antibodies, immunoassays, proteins, and detection kits used by scientists worldwide.

Computational roles increasingly sit within the Danaher Affinity Reagent Autonomous Laboratory hosted at Abcam in Cambridge, where teams apply machine learning to the design of miniproteins, VHHs (nanobodies), and antibodies, then validate designs in a state-of-the-art autonomous wet-lab that enables rapid design/make/test/learn cycles.

The work spans structural biology, computational modeling, and AI-driven molecule design, in close partnership between dry-lab and wet-lab teams.

Being part of Danaher gives access to substantial resources and a broad life-sciences network, while the Cambridge Biomedical Campus offers proximity to one of Europe's strongest biotech and academic ecosystems.

🧬 Bioinformatics Focus

Computational work at Abcam centers on AI - driven biologics design. Core areas:

  • Generative protein design — applying LLM-based and diffusion-based models alongside structure- and physics-based methods to design miniproteins, VHHs/nanobodies, and antibodies;
  • Protein structural modeling and prediction;
  • Optimization of binding, developability, and stability profiles;
  • Integration with immune repertoire sequencing and display technologies (phage/yeast);
  • Building reproducible, production-quality pipelines (Python, ML libraries, MLOps) that close the loop with an autonomous wet-lab. The emphasis is on rapid, iterative design/make/test/learn cycles at scale rather than single-shot analysis.

📈 Career Growth & Development

🎯

Career Tracks

Computational and scientific staff at Abcam typically progress along a scientist track (Research Associate / Scientist → Senior Scientist → Principal Scientist) with parallel leadership paths into data/analytics management.

🔄

Mobility

As a Danaher operating company, Abcam offers exposure to the Danaher Business System and mobility across Danaher's broader life-sciences portfolio.

📚

Development

Development is supported through on-the-job work with cutting-edge AI/ML methods, collaboration across dry- and wet-lab teams, and the resources of a large parent organization.

Get weekly job alerts